期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Wilfoside C3N Promotes Tumor Cell Death by Activating Gammadelta T Cells-Mediated Anti-tumor Immunity
1
作者 HOU Jin-yu WANG Jing 《河北北方学院学报(自然科学版)》 2017年第2期1-10,共10页
Vδ1^+γδ T lymphocytes are known to play important roles in anti-tumor immunity.We recently reported an anti-tumor activity of wilfoside C3 N,an active component extracted from Chinese medicinal herbs.In the current... Vδ1^+γδ T lymphocytes are known to play important roles in anti-tumor immunity.We recently reported an anti-tumor activity of wilfoside C3 N,an active component extracted from Chinese medicinal herbs.In the current study,we evaluated the role of Vδ1^+γδ T cells in C3 N anti-tumor activity using an in vitro cell co-culture model.We found that C3 N induced the ECA109 tumor cells to undergo apoptosis in the presence of Vδ1^+γδ T cells.The level of ECA109 apoptosis maximized when both C3 N and Vδ1 + γδ T cells were present,which correlated with the increased expression of Fas on ECA109 and Fas ligand on Vδ1^+γδ T cells induced by C3 N.In addition,C3 N also enhanced secretion of cytokines,perforin and granzymes by Vδ1^+γδ T cells.These observations suggest that activation of Vδ1^+ γδ T cells may play a critical role in C3N-mediated anti-tumor activity. 展开更多
关键词 wilfoside C3N 1^+gammadelta t cells ANtI-tUMOR ECA109 cells
下载PDF
乳腺癌患者不同病理特征中H3K9ac、PD-L1、VISTA表达及其联合检测对乳腺癌不良预后的预测价值
2
作者 赵杰 陶璐 刘姗姗 《河南医学研究》 CAS 2024年第18期3357-3361,共5页
目的探讨乳腺癌患者不同病理特征中组蛋白H3第9位赖氨酸残基乙酰化(H3K9ac)、程序性死亡因子配体1(PD-L1)、T细胞激活抑制物免疫球蛋白的可变区结构域(VISTA)及其联合检测对乳腺癌不良预后的预测价值。方法选取2018年5月至2020年7月平... 目的探讨乳腺癌患者不同病理特征中组蛋白H3第9位赖氨酸残基乙酰化(H3K9ac)、程序性死亡因子配体1(PD-L1)、T细胞激活抑制物免疫球蛋白的可变区结构域(VISTA)及其联合检测对乳腺癌不良预后的预测价值。方法选取2018年5月至2020年7月平顶山市第一人民医院收治的130例乳腺癌患者,免疫组化检测乳腺癌组织及癌旁组织中H3K9ac、PD-L1及VISTA表达情况。比较乳腺癌组织、癌旁组织中H3K9ac、PD-L1及VISTA表达情况;比较乳腺癌不同病理特征中H3K9ac、PD-L1及VISTA表达情况;随访3 a,根据是否发生转移、复发、死亡分为预后不良和预后良好;比较预后不良和预后良好乳腺癌患者H3K9ac、PD-L1及VISTA表达情况;分析H3K9ac、PD-L1、VISTA表达联合检测对乳腺癌不良预后的预测价值。结果乳腺癌组织中H3K9ac、PD-L1、VISTA高表达率均高于癌旁组织(P<0.05);不同组织分化程度、T分期、N分期、阳性淋巴细胞数目中H3K9ac、PD-L1、VISTA高表达率比较,差异有统计学意义(P<0.05);随访3 a,130例乳腺癌患者失访7例(5.38%),预后不良22例,预后良好101例。预后不良患者H3K9ac、PD-L1、VISTA高表达率高于预后良好患者(P<0.05);H3K9ac、PD-L1、VISTA联合检测预测乳腺癌患者不良预后的AUC为0.902,大于各指标单独预测的0.714、0.866、0.781(P<0.05)。结论乳腺癌患者癌组织中H3K9ac、PD-L1及VISTA均呈高表达,其高表达与分化程度、分期、淋巴细胞数目等病理特征相关,H3K9ac、PD-L1、VISTA联合检测对乳腺癌患者不良预后具有较高的预测价值。 展开更多
关键词 乳腺癌 组蛋白H3第9位赖氨酸残基乙酰化 程序性死亡因子配体1 t细胞激活抑制物免疫球蛋白的可变区结构域 预后
下载PDF
VTCN1调控结肠癌细胞长链非编码RNA和mRNA的全基因表达谱分析 被引量:2
3
作者 褚以忞 周锋利 +5 位作者 徐莹 蒯榕 李吉 侯照远 杨大明 彭海霞 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2019年第3期270-277,共8页
目的·探讨含V-set域T细胞激活抑制因子(V-set domain containing T cell activation inhibitor 1,VTCN1)在结肠癌中对下游长链非编码RNA(long noncoding RNA,lncRNA)和mRNA的调控作用。方法·利用慢病毒质粒在结肠癌细胞株SW1... 目的·探讨含V-set域T细胞激活抑制因子(V-set domain containing T cell activation inhibitor 1,VTCN1)在结肠癌中对下游长链非编码RNA(long noncoding RNA,lncRNA)和mRNA的调控作用。方法·利用慢病毒质粒在结肠癌细胞株SW1116中过表达VTCN1,抽提RNA并测序,与阴性对照组比较分析差异表达的lncRNA和m RNA,并任意选取差异表达的lncRNA(3条)和mRNA(2条)进行实时定量PCR(qRT-PCR)验证RNA测序结果的准确性。通过BLAST2GO和京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)分析预测这些差异表达lncRNA和m RNA的相关功能。利用线上平台GEPIA18(Gene Expression Profiling Interactive Analysis)分析差异表达lncRNA与结直肠癌患者生存期的相关性。结果·通过RNA测序在过表达VTCN1的SW1116细胞中发现了167条差异基因,包括39条lncRNA和128条m RNA。qRT-PCR检验结果与RNA测序结果变化趋势一致。生物信息学分析结果显示这些受VTCN1调控的差异基因可能参与了内质网中的蛋白处理、mRNA监控信号通路。另外,在过表达VTCN1的结肠癌细胞中明显上调的3条lncRNA(DNAJC9-AS1、HCG27和RP11-339B21.13),同时也是预测结直肠癌患者总生存期的独立因子。结论·在结肠癌细胞中VTCN1对下游多条lncRNA和mRNA具有调控作用,这些lncRNA和mRNA可能参与了内质网中的蛋白处理和mRNA监控信号通路。 展开更多
关键词 v-sett细胞激活抑制因子 结肠癌 长链非编码RNA RNA测序 生物信息学分析
下载PDF
γδT cells:Major advances in basic and clinical research in tumor immunotherapy 被引量:1
4
作者 Yueqi Zhao Peng Dong +2 位作者 Wei He Jianmin Zhang Hui Chen 《Chinese Medical Journal》 SCIE CAS CSCD 2024年第1期21-33,共13页
γδT cells are a kind of innate immune T cell.They have not attracted sufficient attention because they account for only a small proportion of all immune cells,and many basic factors related to these cells remain unc... γδT cells are a kind of innate immune T cell.They have not attracted sufficient attention because they account for only a small proportion of all immune cells,and many basic factors related to these cells remain unclear.However,in recent years,with the rapid development of tumor immunotherapy,γδT cells have attracted increasing attention because of their ability to exert cytotoxic effects on most tumor cells without major histocompatibility complex(MHC)restriction.An increasing number of basic studies have focused on the development,antigen recognition,activation,and antitumor immune response ofγδT cells.Additionally,γδT cell-based immunotherapeutic strategies are being developed,and the number of clinical trials investigating such strategies is increasing.This review mainly summarizes the progress of basic research and the clinical application ofγδT cells in tumor immunotherapy to provide a theoretical basis for further the development ofγδT cell-based strategies in the future. 展开更多
关键词 Gamma-delta t-cells t cell receptor CD1A tumor immunotherapy Receptors chimeric antigen 1 cells αβt cells
原文传递
Distinct Pattern of Human Vδ/51 γδ/5 T Cells Recognizing MICA
5
作者 Jianqiang Li Lianxian Cui Wei He 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2005年第4期253-258,共6页
γδ T cells represent one unique recognition pattern, the limited recognition, which distinguishes from the specific recognition for αβ T cells and pattern recognition for macrophages. Vδ1 γδT cell is the major ... γδ T cells represent one unique recognition pattern, the limited recognition, which distinguishes from the specific recognition for αβ T cells and pattern recognition for macrophages. Vδ1 γδT cell is the major subset of human γδT cells, which predominates in mucosal tissue including the intestinal epithelia. Presently, a few antigens that human Vδ1TCR can recognize have been identified. Among them, MHC class I chain-related molecules A (MICA) have been studied most intensively. Besides Vδ1TCR, MICA is also the ligand of NKG2D, a C-type lectin-like activating immunoreceptor. In human, only Vδ1 cells can simultaneously express both types of receptors of MICA while NK cells, αβ T cells and other subsets of γδT cells likewise express NKG2D. Although the precise mechanisms are still enigmatic, this distinct pattern of Vδ1 cells recognizing MICA predicts unique biological significance of Vδ1 cells in immune defense. Recent years, some progresses have been made in this issue. In this review we summarize the related reports and put forward some novel views based on our group's studies. 展开更多
关键词 1tCR MICA NKG2D γδt cell
原文传递
New insights of T cells in the pathogenesis of psoriasis 被引量:50
6
作者 Yihua Cai Chris Fleming Jun Yan 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2012年第4期302-309,共8页
Psoriasis is one of the most common immune-mediated chronic, inflammatory skin diseases characterized by hyperproliferative keratinocytes and infiltration of T cells, dendritic cells, macrophages and neutrophils. Alth... Psoriasis is one of the most common immune-mediated chronic, inflammatory skin diseases characterized by hyperproliferative keratinocytes and infiltration of T cells, dendritic cells, macrophages and neutrophils. Although the pathogenesis of psoriasis is not fully understood, there is ample evidence suggesting that the dysregulation of immune cells in the skin, particularly T cells, plays a critical role in psoriasis development. In this review, we mainly focus on the pathogenic T cells and discuss how these T cells are activated and involved in the disease pathogenesis. Newly identified 'professional' IL-17-producing dermal γδ T cells and their potential role in psoriasis will also be included. Finally, we will briefly summarize the recent progress on the T cell and its related cytokine-targeted therapy for psoriasis treatment. 展开更多
关键词 Psoriasis tH1/tH17 cells gammadelta t cells t cell-targeted theraphy
原文传递
靶向胶质瘤的敲除程序死亡受体-1基因表皮生长因子突变受体Ⅲ嵌合抗原受体T细胞的构建和功能鉴定
7
作者 陈力 闫德祺 +3 位作者 袁紫林 王刚 刘莹 刁波 《中华实验外科杂志》 CAS CSCD 北大核心 2019年第8期1358-1361,共4页
目的构建敲除程序死亡受体-1(PD-1)基因的靶向表皮生长因子突变受体Ⅲ(EGFRvⅢ)阳性胶质瘤细胞的嵌合抗原受体T(CAR-T)细胞,评估其在体外和体内对EGFRvⅢ阳性胶质瘤细胞的杀伤作用.方法运用电转染技术构建靶向EGFRvⅢ抗原的CAR-T细胞,... 目的构建敲除程序死亡受体-1(PD-1)基因的靶向表皮生长因子突变受体Ⅲ(EGFRvⅢ)阳性胶质瘤细胞的嵌合抗原受体T(CAR-T)细胞,评估其在体外和体内对EGFRvⅢ阳性胶质瘤细胞的杀伤作用.方法运用电转染技术构建靶向EGFRvⅢ抗原的CAR-T细胞,并用基因打靶技术(CRISPR/Cas9)敲除其PD-1基因,获得PD-1ko EGFRvⅢCAR-T细胞;流式细胞术、聚合酶链反应(PCR)和酶切法验证PD-1 ko EGFRvⅢCAR-T细胞是否构建成功;流式细胞术及乳酸脱氢酶细胞毒性试剂盒检测PD-1ko EGFRvⅢCAR-T细胞对胶质瘤细胞的杀伤作用.选取15只6~8周龄雌性BALB/c-nude小鼠,构建肿瘤模型,随机分为PD-1ko EGFRvⅢCAR-T细胞组、T细胞组、磷酸盐缓冲液(PBS)组.各组在第28、32和36天分别注入100μl 5×106个PD-1ko CAR-T细胞、T细胞、100 μl PBS.应用SPSS 18.0软件进行统计,计量资料采用均数±标准差表示,两组间均数比较采用t检验,多组间比较采用单因素方差分析.结果 PCR及酶切实验显示PD-1ko EGFRvⅢCAR-T细胞PD-1出现了不同条带,验证基因敲除成功.体外实验中,PD-1ko EGFRvⅢCAR-T细胞分泌的细胞因子浓度[白细胞介素(IL)-2:(242.08±19.08) ng/L,干扰素(IFN)-γ:(8 374.8 ±265.82) ng/L]均显著高于T细胞组[IL-2:(153.73±13.23) ng/L,IFN-γ:(2 118.96±29.62) ng/L],差异有统计学意义(IL-2:t=6.589,P< 0.05;IFN-γ:t=33.076,P< 0.05).细胞毒性实验结果显示PD-1 koEGFRvⅢCAR-T组对胶质瘤细胞杀伤作用显著高于T细胞组及PBS组,且效靶比越高杀伤作用越强.移植瘤裸鼠注射细胞后,PD-1ko EGFRvⅢCAR-T组瘤体体积为(1.06±0.26) cm3,显著小于T细胞的(5.14±1.57) cm3和PBS对照组组瘤体体积为(5.04 ±0.61) cm3,3组比较差异均有统计学意义(F=22.290,P<0.05).结论 PD-1 ko EGFRvⅢCAR-T细胞具有良好的抑瘤效果. 展开更多
关键词 嵌合抗原受体t细胞 胶质瘤 程序性死亡受体1 表皮生长因子突变受体Ⅲ
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部